SEQUENOM (SQNM) Delays Launch of SEQureDx After Test Results Mishandled
More News related to SQNM
- Trading Overview for Sequenom Inc. Issued by StockPreacher.com
- After-Hours Movers 11/09: SGK, PCLN, SQNM Higher; MBI, SDTH, UTK, TOPS, CPST, BTN, FLR Lower
- Sequenom (SQNM) Tops Q3 EPS by 4c
- Sequenom Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
More News related to FDA
- Cornerstone Therapeutics (CRTX) Receives Warning Letter From FDA
- Pfizer (PFE) Gets Okay for Bipolar Treatment Geodon from U.S. FDA
- Intuitive Surgical (ISRG) Receives Japanese Approval for da Vinci
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Boston Scientific (BSX) Receives 510(k) Clearance and CE Mark on WallFlex
SEQUENOM, Inc. (NASDAQ: SQNM) announced that the expected launch of its SEQureDx Down syndrome test is delayed, due to the discovery by company officials of employee mishandling of R&D test data and results.
Accordingly the company is no longer relying on the previously announced R&D test data and results. SEQUENOM has not changed its plans to develop in parallel its RNA- and DNA-based methods for the Down syndrome test and will endeavor to have a validated test in the fourth quarter of 2009. Under the circumstances, and as supported by key clinical opinion leaders, the company now intends to launch the Down syndrome test upon publication in a peer-reviewed journal of the results from the on-going large, independent clinical studies, which are designed to be practice-changing for Down syndrome testing.
Related Categories
FDAHot List
Stocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
